Search

Your search keyword '"KIM, SEUNG TAE"' showing total 1,468 results
Start Over Author "KIM, SEUNG TAE"
1,468 results on '"KIM, SEUNG TAE"'

1. Highly tunable moir\'e superlattice potentials in twisted hexagonal boron nitrides

Author

Han, Kwanghee, Cho, Minhyun, Kim, Taehyung, Kim, Seung Tae, Kim, Suk Hyun, Park, Sang Hwa, Yang, Sang Mo, Watanabe, Kenji, Taniguchi, Takashi, Menon, Vinod, and Kim, Young Duck

Subjects
Condensed Matter - Mesoscale and Nanoscale Physics, Condensed Matter - Materials Science, Physics - Applied Physics
Abstract

Moir\'e superlattice of twisted hexagonal boron nitride (hBN) has emerged as an advanced atomically thin van der Waals interfacial ferroelectricity platform. Nanoscale periodic ferroelectric moir\'e domains with out-of-plane potentials in twisted hBN allow the hosting of remote Coulomb superlattice potentials to adjacent two-dimensional materials for tailoring strongly correlated properties. Therefore, the new strategies for engineering moir\'e length, angle, and potential strength are essential for developing programmable quantum materials and advanced twistronics applications devices. Here, we demonstrate the realization of twisted hBN-based moir\'e superlattice platforms and visualize the moir\'e domains and ferroelectric properties using Kelvin probe force microscopy. Also, we report the KPFM result of regular moir\'e superlattice in the large area. It offers the possibility to reproduce uniform moir\'e structures with precise control piezo stage stacking and heat annealing. We demonstrate the high tunability of twisted hBN moir\'e platforms and achieve cumulative multi-ferroelectric polarization and multi-level domains with multiple angle mismatched interfaces. Additionally, we observe the quasi-1D anisotropic moir\'e domains and show the highest resolution analysis of the local built-in strain between adjacent hBN layers compared to the conventional methods. Furthermore, we demonstrate in-situ manipulation of moir\'e superlattice potential strength using femtosecond pulse laser irradiation, which results in the optical phonon-induced atomic displacement at the hBN moir\'e interfaces. Our results pave the way to develop precisely programmable moir\'e superlattice platforms and investigate strongly correlated physics in van der Waals heterostructures., Comment: 26 pages, 4 figures

Published
2024
Full Text
View/download PDF

8. FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

Author

Klempner, Samuel J, Madison, Russell, Pujara, Vivek, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj M, Schrock, Alexa B, Kim, Seung Tae, Maron, Steven B, Dayyani, Farshid, Catenacci, Daniel VT, Lee, Jeeyun, and Chao, Joseph

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Genetics, Clinical Research, Good Health and Well Being, Adenocarcinoma, Biomarkers, Tumor, Esophageal Neoplasms, Esophagogastric Junction, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Mutation, Prognosis, Receptor, Fibroblast Growth Factor, Type 2, Retrospective Studies, Stomach Neoplasms, Fibroblast growth factor receptor 2, Gastric cancer, Gastroesophageal junction adenocarcinoma, Heterogeneity, Receptor tyrosine kinase, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BACKGROUND:With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited success. Recurrent fibroblast growth factor receptor 2 (FGFR2) alterations exist in GEA; however, little is known about the genomic landscape of FGFR2-altered GEA. We examined FGFR2 alteration frequency and frequency of co-occurring alterations in GEA. SUBJECTS, MATERIALS, AND METHODS:A total of 6,667 tissue specimens from patients with advanced GEA were assayed using hybrid capture-based genomic profiling. Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA, and microsatellite instability was determined on 95 or 114 loci. Descriptive statistics were used to compare subgroups. RESULTS:We identified a total of 269 (4.0%) FGFR2-altered cases consisting of FGFR2-amplified (amp; 193, 72% of FGFR2-altered), FGFR2-mutated (36, 13%), FGFR2-rearranged (re; 23, 8.6%), and cases with multiple FGFR2 alterations (17, 6.3%). Co-occurring alterations in other GEA RTK targets including ERBB2 (10%), EGFR (8%), and MET (3%) were observed across all classes of FGFR2-altered GEA. Co-occurring alterations in MYC (17%), KRAS (10%), and PIK3CA (5.6%) were also observed frequently. Cases with FGFR2amp and FGFR2re were exclusively microsatellite stable. The median TMB for FGFR2-altered GEA was 3.6 mut/mb, not significantly different from a median of 4.3 mut/mb seen in FGFR2 wild-type samples. CONCLUSION:FGFR2-altered GEA is a heterogenous subgroup with approximately 20% of FGFR2-altered samples harboring concurrent RTK alterations. Putative co-occurring modifiers of FGFR2-directed therapy including oncogenic MYC, KRAS, and PIK3CA alterations were also frequent, suggesting that pretreatment molecular analyses may be needed to facilitate rational combination therapies and optimize patient selection for clinical trials. IMPLICATIONS FOR PRACTICE:Actionable receptor tyrosine kinase alterations assayed within a genomic context with therapeutic implications remain limited to HER2 amplification in gastroesophageal adenocarcinomas (GEA). Composite biomarkers and heterogeneity assessment are critical in optimizing patients selected for targeted therapies in GEA. Comprehensive genomic profiling in FGFR2-altered GEA parallels the heterogeneity findings in HER2-amplified GEA and adds support to the utility of genomic profiling in advanced gastroesophageal adenocarcinomas.

Published
2019

11. Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab.

Author

KIM, RYUL, PARK, JOO KYUNG, KWON, MINSUK, AN, MINAE, HONG, JUNG YONG, PARK, JOON OH, LIM, SUNG HEE, and KIM, SEUNG TAE

Subjects
BILIARY tract cancer, SOMATIC mutation, REFERENCE values, IMMUNE checkpoint inhibitors, KILLER cells
Abstract

Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial. Materials and methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy. Results: All patients had microsatellite stable (MSS) type tumors. Three of the 32 patients achieved partial response (PR), with an objective response rate (ORR) of 9.4% (95% confidence interval [CI], 2.0–25.2) and nine showed stable disease (SD), exhibiting a disease control rate (DCR) of 37.5% (95% CI, 21.1–56.3). For the 31 patients who had access to PD-1 ligand 1 (PD-L1) combined positive score (CPS) testing (cut-off value ≥1%), the ORR was not different between those who had PD-L1-positive (PD-L1+; 1/11, 9.1%) and PDL1-(2/20, 10.0%) tumors (p = 1.000). The tumor mutational burden (TMB) of PD-L1+ BTC was comparable to that of PD-L1-BTC (p = 0.630). TMB and any exonic somatic mutations were also not predictive of pembrolizumab response. Molecular analysis of blood and tumor samples demonstrated a relatively high natural killer (NK) cell proportion in the peripheral blood before pembrolizumab treatment in patients who achieved tumor response. Moreover, the tumors of these patients presented high enrichment scores for NK cells, antitumor cytokines, and Th1 signatures, and a low enrichment score for cancer-associated fibroblasts. Conclusions: This study shows the molecular characteristics associated with the efficacy of pembrolizumab in BTC of the MSS type. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

13. Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement

Author

Lee, Jeong Ha, primary, Kim, Nalee, additional, Yu, Jeong Il, additional, Yoo, Gyu Sang, additional, Park, Hee Chul, additional, Lee, Woo-Yong, additional, Yun, Seong Hyeon, additional, Kim, Hee Cheol, additional, Cho, Yong Beom, additional, Huh, Jung Wook, additional, Park, Yoon Ah, additional, Shin, Jung Kyong, additional, Park, Joon Oh, additional, Kim, Seung Tae, additional, Park, Young Suk, additional, Lee, Jeeyun, additional, and Kang, Won Ki, additional

Published
2024
Full Text
View/download PDF

17. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Author

Yen, Ivana, Shanahan, Frances, Lee, Jeeyun, Hong, Yong Sang, Shin, Sang Joon, Moore, Amanda R., Sudhamsu, Jawahar, Chang, Matthew T., Bae, Inhwan, Dela Cruz, Darlene, Hunsaker, Thomas, Klijn, Christiaan, Liau, Nicholas P. D., Lin, Eva, Martin, Scott E., Modrusan, Zora, Piskol, Robert, Segal, Ehud, Venkatanarayan, Avinashnarayan, Ye, Xin, Yin, Jianping, Zhang, Liangxuan, Kim, Jin-Soo, Lim, Hyeong-Seok, Kim, Kyu-Pyo, Kim, Yu Jung, Han, Hye Sook, Lee, Soo Jung, Kim, Seung Tae, Jung, Minkyu, Hong, Yoon-hee, Noh, Young Su, Choi, Munjeong, Han, Oakpil, Nowicka, Malgorzata, Srinivasan, Shrividhya, Yan, Yibing, Kim, Tae Won, and Malek, Shiva

Published
2021
Full Text
View/download PDF

18. The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer.

Author

Lim, Sung Hee, Kim, Min Jung, Lee, Jeeyun, Lim, Ho Yeong, Kang, Won Ki, and Kim, Seung Tae

Subjects
STOMACH tumors, SALVAGE therapy, IMMUNE checkpoint inhibitors, GENE expression, IMMUNOHISTOCHEMISTRY, KAPLAN-Meier estimator, ONCOGENES, DRUG efficacy, SURVIVAL analysis (Biometry), PROGRESSION-free survival, DISEASE progression, PHARMACODYNAMICS
Abstract

Simple Summary: This study evaluated the effectiveness of salvage pembrolizumab in advanced gastric cancer (AGC) patients based on HER2 expression. Conducted at Samsung Medical Center from November 2017 to March 2023, it involved 113 patients treated with pembrolizumab. Twelve patients (10.6%) were HER2-positive, and 101 were HER2-negative. Results showed no complete responses among 92 evaluable patients. However, 50% of HER2-positive patients had a partial response compared to 4.9% of HER2-negative patients (p < 0.001). Disease control rates were 70% for HER2-positive and 37.8% for HER2-negative patients (p = 0.086). Median progression-free survival was 5.53 months for HER2-positive patients versus 1.81 months for HER2-negative patients (p = 0.037). This indicates that salvage pembrolizumab monotherapy is more effective in HER2-positive AGC patients. Immune checkpoint inhibitors (ICIs) are used as salvage treatments for advanced gastric cancer (AGC) regardless of HER2 status. This study assessed the efficacy of ICIs based on HER2 expression in AGC patients who received pembrolizumab as salvage monotherapy at Samsung Medical Center from November 2017 to March 2023. HER2 status was determined via immunohistochemistry, and tumor response and survival outcomes were compared accordingly. Among the 113 patients analyzed, with a median age of 61 years and 64.6% being male, 12 patients (10.6%) were HER2-positive, and 101 patients (89.4%) were HER2-negative. Of 92 evaluable patients, none had a complete response. However, 50% of HER2-positive patients had a partial response, compared to 4.9% of HER2-negative patients (p < 0.001). The disease control rate was 70% in HER2-positive and 37.8% in HER2-negative patients (p = 0.086). Median progression-free survival was 5.53 months for HER2-positive patients versus 1.81 months for HER2-negative patients (p = 0.037). Pembrolizumab as a salvage chemotherapy for the treatment of AGC demonstrated superior effectiveness in HER2-positive patients compared with HER2-negative patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Figure S12 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Author

An, Minae, primary, Mehta, Arnav, primary, Min, Byung Hoon, primary, Heo, You Jeong, primary, Wright, Samuel J., primary, Parikh, Milan, primary, Bi, Lynn, primary, Lee, Hyuk, primary, Kim, Tae Jun, primary, Lee, Song-Yi, primary, Moon, Jeonghyeon, primary, Park, Ryan J., primary, Strickland, Matthew R., primary, Park, Woong-Yang, primary, Kang, Won Ki, primary, Kim, Kyoung-Mee, primary, Kim, Seung Tae, primary, Klempner, Samuel J., primary, and Lee, Jeeyun, primary

Published
2024
Full Text
View/download PDF

21. Table S7 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Author

An, Minae, primary, Mehta, Arnav, primary, Min, Byung Hoon, primary, Heo, You Jeong, primary, Wright, Samuel J., primary, Parikh, Milan, primary, Bi, Lynn, primary, Lee, Hyuk, primary, Kim, Tae Jun, primary, Lee, Song-Yi, primary, Moon, Jeonghyeon, primary, Park, Ryan J., primary, Strickland, Matthew R., primary, Park, Woong-Yang, primary, Kang, Won Ki, primary, Kim, Kyoung-Mee, primary, Kim, Seung Tae, primary, Klempner, Samuel J., primary, and Lee, Jeeyun, primary

Published
2024
Full Text
View/download PDF

22. Data from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Author

An, Minae, primary, Mehta, Arnav, primary, Min, Byung Hoon, primary, Heo, You Jeong, primary, Wright, Samuel J., primary, Parikh, Milan, primary, Bi, Lynn, primary, Lee, Hyuk, primary, Kim, Tae Jun, primary, Lee, Song-Yi, primary, Moon, Jeonghyeon, primary, Park, Ryan J., primary, Strickland, Matthew R., primary, Park, Woong-Yang, primary, Kang, Won Ki, primary, Kim, Kyoung-Mee, primary, Kim, Seung Tae, primary, Klempner, Samuel J., primary, and Lee, Jeeyun, primary

Published
2024
Full Text
View/download PDF

28. ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer

Author

Yu, Jeong Il, Yoo, Gyu Sang, Park, Hee Chul, Choi, Doo Ho, Lee, Woo Yong, Yun, Seong Hyeon, Kim, Hee Cheol, Cho, Yong Beom, Huh, Jung Wook, Park, Yoon Ah, Shin, Jung Kyong, Park, Joon Oh, Kim, Seung Tae, Park, Young Suk, Lee, Jeeyun, Kang, Won Ki, Lim, Ho Yeong, and Hong, Jung Yong

Published
2022
Full Text
View/download PDF

34. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Author

An, Minae, primary, Mehta, Arnav, additional, Min, Byung Hoon, additional, Heo, You Jeong, additional, Wright, Samuel J., additional, Parikh, Milan, additional, Bi, Lynn, additional, Lee, Hyuk, additional, Kim, Tae Jun, additional, Lee, Song-Yi, additional, Moon, Jeonghyeon, additional, Park, Ryan J., additional, Strickland, Matthew R., additional, Park, Woong-Yang, additional, Kang, Won Ki, additional, Kim, Kyoung-Mee, additional, Kim, Seung Tae, additional, Klempner, Samuel J., additional, and Lee, Jeeyun, additional

Published
2024
Full Text
View/download PDF

35. Predictive role of homologous recombination deficiency (HRD) for irinotecan in combination with venadaparib, a novel PARP1/2 inhibitor, as third- or fourth-line treatment in patients with advanced gastric cancer.

Author

Oh, Do-Youn, primary, Ryu, Min-Hee, additional, Lee, Keun-Wook, additional, Rha, Sun Young, additional, Kim, Seung Tae, additional, Iqbal, Syma, additional, Yoon, Jeesun, additional, Kim, Hyung-Don, additional, Kim, Jin Won, additional, Kim, Ji-Won, additional, Lee, Won Sik, additional, Hong, Min Ju, additional, Lee, Myongjae, additional, Roh, Eun-Jihn, additional, and HA, KYOUNG SOO, additional

Published
2024
Full Text
View/download PDF

36. BOLD-100-001 (TRIO039): A phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX—Efficacy and safety analysis.

Author

Spratlin, Jennifer L., primary, O'Kane, Grainne M., additional, Oh, Do-Youn, additional, Rha, Sun Young, additional, McWhirter, Elaine, additional, Elimova, Elena, additional, Kavan, Petr, additional, Choi, Moon Ki, additional, Kim, Dae Won, additional, Goodwin, Rachel Anne, additional, Hecht, J. Randolph, additional, Kim, Seung Tae, additional, Koo, Dong-Hoe, additional, Halani, Khalif, additional, McAllister, E. Russell, additional, Jones, Michelle, additional, Snow, Malcolm, additional, Lemmerick, Yasmin, additional, Spera, Gonzalo, additional, and Pankovich, Jim, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results